Sofinnova Ventures | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/Sofinnova Ventures/Activity

Sofinnova Ventures Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Investment

Participated in Expedition Therapeutics' oversubscribed $115M Series B to advance a next-generation DPP1 inhibitor for COPD.

Expedition Therapeutics

Expedition Therapeutics Sofinnova Ventures

businesswire.comAUG 5, 2026

AUG 5, 2026

Investment

Participated in Claris Bio's $118M Series B financing supporting a planned pivotal study in LSCD.

Claris Bio

Claris Bio Sofinnova Ventures

globenewswire.comJUL 28, 2026

JUL 28, 2026

Milestone

Portfolio company Vera Therapeutics received FDA accelerated approval for TRUTAKNA (atacicept) in IgA Nephropathy.

Vera Therapeutics

Vera Therapeutics Sofinnova Ventures

veratx.comJUL 2026

JUL 2026

Investment

New investor in City Therapeutics' $99.5M Series B to advance next-generation RNAi therapeutics; Maha Radhakrishnan joined the board as observer.

City Therapeutics

City Therapeutics Sofinnova Ventures

businesswire.comJUN 8, 2026

JUN 8, 2026

Milestone

Portfolio company Avenzo Therapeutics announced a merger agreement with Rallybio alongside a $215M concurrent placement.

Avenzo Therapeutics

Avenzo Therapeutics Sofinnova Ventures

sofinnova.comJUN 2026

JUN 2026

Milestone

Portfolio program Baxfendy received FDA approval as the first aldosterone synthase inhibitor.

Baxfendy

BaxfendySofinnova Ventures

sofinnova.comMAY 2026

MAY 2026

Investment

Led Coultreon Biopharma's oversubscribed $125M Series A (co-led with Forbion and Novo Holdings) to advance its SIK3 inhibitor immunology pipeline.

Coultreon Biopharma

Coultreon Biopharma Sofinnova Ventures

globenewswire.comAPR 28, 2026

APR 28, 2026

Milestone

Portfolio company Seaport Therapeutics announced upsized IPO pricing.

Seaport Therapeutics

Seaport Therapeutics Sofinnova Ventures

seaporttx.comAPR 2026

APR 2026

News

Firm reported cumulative track record as of March 31, 2026: 120 companies funded, 55 IPOs, 33 M&A exits, and 36 FDA drug approvals.

Track record milestone: 120 companies funded, 55 IPOs, 33 M&As, 36 FDA approvals

Sofinnova Ventures

sofinnova.comMAR 2026

MAR 2026

Milestone

Portfolio company BioAge Labs completed an upsized $115M public offering.

BioAge Labs

BioAge Labs Sofinnova Ventures

bioagelabs.comJAN 2026

JAN 2026

Exit

Portfolio company Capstan Therapeutics was acquired by AbbVie for up to $2.1B, closing August 19, 2025.

Capstan Therapeutics

Capstan Therapeutics Sofinnova Ventures

news.abbvie.comAUG 19, 2025

AUG 19, 2025

Milestone

Portfolio company Alkeus Pharmaceuticals reported positive interim results in Stargardt disease.

Alkeus Pharmaceuticals

Alkeus Pharmaceuticals Sofinnova Ventures

sofinnova.comAUG 2025

AUG 2025

Investment

Co-led (with B Capital) ARTBIO's $132M Series B to advance a pipeline of alpha radioligand therapies and expand manufacturing infrastructure.

ARTBIO

ARTBIO Sofinnova Ventures

prnewswire.comJUL 29, 2025

JUL 29, 2025

Exit

Portfolio company Karuna Therapeutics (NASDAQ: KRTX) was acquired by Bristol Myers Squibb.

Karuna Therapeutics

Karuna Therapeutics Sofinnova Ventures

sofinnova.comMAR 2024

MAR 2024

Page 1 of 2